用基因编辑iPS细胞进行基因疗法,以向恶性质瘤
Ryota Tamura1, Hiroyuki Miyoshi1,2,3,4,5, Kent Imaizumi2
1Department of Neurosurgery Keio University School of Medicine Shinjuku-ku, Tokyo Japan.
Bioengineering & translational medicine
|September 11, 2023
概括
来自人类诱导的多能干细胞 (hiPSCs) 的基因组编辑的神经干细胞 (NSCs) 显示出对质母细胞瘤的增强迁移和抗瘤作用. 这种新型基因疗法方法对治疗侵入性质瘤干细胞 (GSCs) 是有前途的.
科学领域:
- 干细胞生物学 干细胞生物学
- 癌症研究 癌症研究
- 基因治疗是一种基因疗法.
背景情况:
- 质母细胞瘤 (GBM) 是一种高度侵入性的脑瘤,预后不佳.
- 侵入性质瘤干细胞 (GSCs) 导致治疗失败和瘤复发.
- 迫切需要针对侵入性GSC的新型治疗策略.
研究的目的:
- 研究CRISPR/Cas9编辑的人类诱导多能干干细胞衍生神经干细胞 (hiPSC-NSCs) 对质母细胞瘤的治疗潜力.
- 评估hiPSC-NSCs与间酶体干细胞 (MSCs) 相比的迁移能力和抗瘤作用.
- 探索hiPSC-NSC迁移的潜在机制,并确定治疗疗效的预测生物标志物.
主要方法:
- 基因编辑CRISPR/Cas9的hiPSCs获得自杀基因表达NSCs.
- 在体外和体内对hiPSC-NSC和MSC之间迁移能力的比较分析.
- 对参与hiPSC-NSC迁移的信号通路 (EphB-ephrinB,CXCL12-CXCR4) 的研究.
- 在质母细胞瘤模型中评估抗瘤效应,ferroptosis诱导和免疫反应.
- 分析基因表达 (thymidylate synthase,dihydroprimidine dehydrogenase) 作为预测生物标志物.
主要成果:
- 与MSC相比,hiPSC-NSCs表现出优越的瘤营养迁移能力,导致显著的体内抗瘤效应.
- 高迁移能力与EphB-ephrinB和CXCL12-CXCR4信号通路有关.
- 将基因插入ACTB位点确保了稳定和高的转基因表达.
- 观察到铁亡并与增强的抗瘤免疫反应相关.
- 甲基胺酸合成酶和二甲胺脱酶表达水平预测了hiPSC-NSC治疗的疗效.
结论:
- 基因组编辑的hiPSC-NSCs显示出作为侵袭性GSCs的基因治疗的巨大潜力.
- 该研究阐明了增强干细胞迁移的机制,并确定了用于质母细胞瘤治疗的预测生物标志物.
- 这项研究为推进基于hiPSC的基因治疗向临床应用提供了一个平台.
更多相关视频
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
1.7K
相关概念视频
Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...
iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
